Changzhou Qianhong Biopharma Co (SZSE:002550) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Changzhou Qianhong Biopharma Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Changzhou Qianhong Biopharma Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Changzhou Qianhong Biopharma Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Changzhou Qianhong Biopharma Co (SZSE:002550) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Changzhou Qianhong Biopharma Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Changzhou Qianhong Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022

Website

http://www.qhsh.com.cn

Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.

Executives

Huang Jie	Executives
Wang Ke	Directors, executives
Jiang Wen Qun	Supervisors
Zou Shao Bo	Executives
Wei Li Jun	Executives
Mei Chun Wei	Executives
Zhou Xiang	Directors, executives
Zhao Gang	Director
Ye Hong Ping	Executives
Liu Jun	Director
Fan Yong	Executives
Jiang Jian Ping	Supervisors
Wang Yao Fang	Director
Hai Tao	Directors, executives
Wang Yi	Director

Changzhou Qianhong Biopharma Co Headlines

No Headlines